The investigative burden of membranous nephropathy in the United KingdomCitation formats

  • External authors:
  • Patrick Hamilton
  • Fiona Wilson
  • Rajkumar Chinnadurai
  • Smeeta Sinha
  • Malinder Singh
  • Arvind Ponnusamy
  • Peter Hall
  • Ajay Dhaygude
  • Durga Kanigicherla

Standard

The investigative burden of membranous nephropathy in the United Kingdom. / Hamilton, Patrick; Wilson, Fiona; Chinnadurai, Rajkumar; Sinha, Smeeta; Singh, Malinder; Ponnusamy, Arvind; Hall, Peter; Dhaygude, Ajay; Kanigicherla, Durga; Brenchley, Paul.

In: Clinical Kidney Journal, 23.04.2019.

Research output: Contribution to journalArticlepeer-review

Harvard

Hamilton, P, Wilson, F, Chinnadurai, R, Sinha, S, Singh, M, Ponnusamy, A, Hall, P, Dhaygude, A, Kanigicherla, D & Brenchley, P 2019, 'The investigative burden of membranous nephropathy in the United Kingdom', Clinical Kidney Journal. https://doi.org/10.1093/ckj/sfz036

APA

Hamilton, P., Wilson, F., Chinnadurai, R., Sinha, S., Singh, M., Ponnusamy, A., Hall, P., Dhaygude, A., Kanigicherla, D., & Brenchley, P. (2019). The investigative burden of membranous nephropathy in the United Kingdom. Clinical Kidney Journal. https://doi.org/10.1093/ckj/sfz036

Vancouver

Hamilton P, Wilson F, Chinnadurai R, Sinha S, Singh M, Ponnusamy A et al. The investigative burden of membranous nephropathy in the United Kingdom. Clinical Kidney Journal. 2019 Apr 23. https://doi.org/10.1093/ckj/sfz036

Author

Hamilton, Patrick ; Wilson, Fiona ; Chinnadurai, Rajkumar ; Sinha, Smeeta ; Singh, Malinder ; Ponnusamy, Arvind ; Hall, Peter ; Dhaygude, Ajay ; Kanigicherla, Durga ; Brenchley, Paul. / The investigative burden of membranous nephropathy in the United Kingdom. In: Clinical Kidney Journal. 2019.

Bibtex

@article{349b76e10f9a41c49ff0499e6eba9095,
title = "The investigative burden of membranous nephropathy in the United Kingdom",
abstract = "BackgroundMembranous nephropathy (MN) represents two distinct disease entities. Primary MN is now recognized as an autoimmune condition associated with the anti-PLA2R antibody and secondary MN occurs in tandem with malignancy, infection, drug therapy and other autoimmune conditions. Prior to the development of accessible enzyme-linked immunosorbent assays, the diagnosis of MN was one of exclusion. We studied whether the introduction of serum anti-PLA2R antibody testing leads to a reduction in the frequency of investigations in MN patients.MethodsPatients from three UK centres with a diagnosis of MN between 2009 and 2014 were identified. We compared patients who had a positive anti-PLA2R test within 6 months of biopsy with those who had no test or a negative test. Records were reviewed for investigations that took place 6 months prior to and 6 months following the biopsy date to see if these were normal or identified a secondary cause of MN.ResultsIn total, 184 patients were included: 80 had no test, 66 had a negative anti-PLA2R test and 38 had a positive test within 6 months of diagnosis. In 2012, 46.5% of patients had an anti-PLA2R test, increasing to 93.3% in 2014. From 2012 to 2014 the number of screening tests dropped from 10.03 to 4.29 and the costs from £497.92 to £132.94.ConclusionsSince its introduction, a progressively higher proportion of patients diagnosed with MN had an anti-PLA2R test. This has led to a reduction in the number of screening tests and in the cost of investigations carried out. The anti-PLA2R test has the potential to reduce this burden as its use becomes more widespread.",
author = "Patrick Hamilton and Fiona Wilson and Rajkumar Chinnadurai and Smeeta Sinha and Malinder Singh and Arvind Ponnusamy and Peter Hall and Ajay Dhaygude and Durga Kanigicherla and Paul Brenchley",
year = "2019",
month = apr,
day = "23",
doi = "10.1093/ckj/sfz036",
language = "English",
journal = "CKJ: Clinical Kidney Journal",
issn = "2048-8505",
publisher = "Oxford University Press",

}

RIS

TY - JOUR

T1 - The investigative burden of membranous nephropathy in the United Kingdom

AU - Hamilton, Patrick

AU - Wilson, Fiona

AU - Chinnadurai, Rajkumar

AU - Sinha, Smeeta

AU - Singh, Malinder

AU - Ponnusamy, Arvind

AU - Hall, Peter

AU - Dhaygude, Ajay

AU - Kanigicherla, Durga

AU - Brenchley, Paul

PY - 2019/4/23

Y1 - 2019/4/23

N2 - BackgroundMembranous nephropathy (MN) represents two distinct disease entities. Primary MN is now recognized as an autoimmune condition associated with the anti-PLA2R antibody and secondary MN occurs in tandem with malignancy, infection, drug therapy and other autoimmune conditions. Prior to the development of accessible enzyme-linked immunosorbent assays, the diagnosis of MN was one of exclusion. We studied whether the introduction of serum anti-PLA2R antibody testing leads to a reduction in the frequency of investigations in MN patients.MethodsPatients from three UK centres with a diagnosis of MN between 2009 and 2014 were identified. We compared patients who had a positive anti-PLA2R test within 6 months of biopsy with those who had no test or a negative test. Records were reviewed for investigations that took place 6 months prior to and 6 months following the biopsy date to see if these were normal or identified a secondary cause of MN.ResultsIn total, 184 patients were included: 80 had no test, 66 had a negative anti-PLA2R test and 38 had a positive test within 6 months of diagnosis. In 2012, 46.5% of patients had an anti-PLA2R test, increasing to 93.3% in 2014. From 2012 to 2014 the number of screening tests dropped from 10.03 to 4.29 and the costs from £497.92 to £132.94.ConclusionsSince its introduction, a progressively higher proportion of patients diagnosed with MN had an anti-PLA2R test. This has led to a reduction in the number of screening tests and in the cost of investigations carried out. The anti-PLA2R test has the potential to reduce this burden as its use becomes more widespread.

AB - BackgroundMembranous nephropathy (MN) represents two distinct disease entities. Primary MN is now recognized as an autoimmune condition associated with the anti-PLA2R antibody and secondary MN occurs in tandem with malignancy, infection, drug therapy and other autoimmune conditions. Prior to the development of accessible enzyme-linked immunosorbent assays, the diagnosis of MN was one of exclusion. We studied whether the introduction of serum anti-PLA2R antibody testing leads to a reduction in the frequency of investigations in MN patients.MethodsPatients from three UK centres with a diagnosis of MN between 2009 and 2014 were identified. We compared patients who had a positive anti-PLA2R test within 6 months of biopsy with those who had no test or a negative test. Records were reviewed for investigations that took place 6 months prior to and 6 months following the biopsy date to see if these were normal or identified a secondary cause of MN.ResultsIn total, 184 patients were included: 80 had no test, 66 had a negative anti-PLA2R test and 38 had a positive test within 6 months of diagnosis. In 2012, 46.5% of patients had an anti-PLA2R test, increasing to 93.3% in 2014. From 2012 to 2014 the number of screening tests dropped from 10.03 to 4.29 and the costs from £497.92 to £132.94.ConclusionsSince its introduction, a progressively higher proportion of patients diagnosed with MN had an anti-PLA2R test. This has led to a reduction in the number of screening tests and in the cost of investigations carried out. The anti-PLA2R test has the potential to reduce this burden as its use becomes more widespread.

U2 - 10.1093/ckj/sfz036

DO - 10.1093/ckj/sfz036

M3 - Article

JO - CKJ: Clinical Kidney Journal

JF - CKJ: Clinical Kidney Journal

SN - 2048-8505

ER -